Our study found that the use of GLP-1 agonist therapy is associated with a lower risk of all-cause mortality, hospitalization, cardiac arrest, acute HF, and cardiogenic shock in this high-risk population. The gene discussed is GLP1R; the disease is cardiac arrest.